768 results on '"Yndestad, Arne"'
Search Results
2. Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data
3. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
4. Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
5. Continuous infusion of resolvin D2 in combination with Angiotensin-II show contrary effects on blood pressure and intracardiac artery remodeling
6. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
7. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study
8. Absence of NLRP3 Inflammasome in Hematopoietic Cells Reduces Adverse Remodeling After Experimental Myocardial Infarction
9. Legumain is upregulated in acute cardiovascular events and associated with improved outcome - potentially related to anti-inflammatory effects on macrophages
10. Relationships of Work Productivity and Activity Impairment with Patient‐Reported Outcomes in Ankylosing Spondylitis: Results from Two Trials
11. IL-18 and IL-18 binding protein are related to disease severity and parasitemia during falciparum malaria
12. Homeostatic Chemokines and Prognosis in Patients With Acute Coronary Syndromes
13. Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction
14. Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction
15. Relationships of Work Productivity and Activity Impairment With Patient‐Reported Outcomes in Ankylosing Spondylitis: Results From Two Trials.
16. Soluble IL-1 receptor 2 is associated with left ventricular remodelling in patients with ST-elevation myocardial infarction
17. Serum neutrophil gelatinase-associated lipocalin (NGAL) concentration is independently associated with mortality in patients with acute coronary syndrome
18. NLRP3 inflammasome deficiency attenuates metabolic disturbances involving alterations in the gut microbial profile in mice exposed to high fat diet
19. Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme
20. Relationships of Work Productivity and Activity Impairment With Patient‐ReportedOutcomes in Ankylosing Spondylitis: Results From Two Trials
21. Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure
22. Rosuvastatin alters the genetic composition of the human gut microbiome
23. Plasma levels of interleukin 27 in falciparum malaria is increased independently of co-infection with HIV: potential immune-regulatory role during malaria
24. NLRP3 inflammasome: a novel player in metabolically-induced inflammation – potential influence on the myocardium
25. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
26. Low Circulating Levels of Mitochondrial and High Levels of Nuclear DNA Predict Mortality in Chronic Heart Failure
27. Altered Levels of Fatty Acids and Inflammatory and Metabolic Mediators in Epicardial Adipose Tissue in Patients With Systolic Heart Failure
28. Increased expression of NAMPT in PBMC from patients with acute coronary syndrome and in inflammatory M1 macrophages
29. Impaired HDL Function Amplifies Systemic Inflammation in Common Variable Immunodeficiency
30. Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
31. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
32. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis
33. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
34. Plain language summary for the manuscript: Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
35. Enhanced Publication Content for the manuscript: Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
36. sj-docx-1-tab-10.1177_1759720X221149965 – Supplemental material for Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
37. Wnt5a is elevated in heart failure and affects cardiac fibroblast function
38. S775 Major Cardiovascular Adverse Events by Baseline Cardiovascular Risk Stratification in Patients With Ulcerative Colitis Treated With Tofacitinib: Data From the OCTAVE Clinical Program
39. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
40. Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
41. Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction
42. Su1809 ASSESSMENT OF STEROID USE IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS WHO INITIATED A NEW JANUS KINASE INHIBITOR OR TUMOR NECROSIS FACTOR INHIBITOR USING DATA FROM A UNITED STATES CLAIMS DATABASE
43. Intracellular Complement Component 3 Attenuated Ischemia-Reperfusion Injury in the Isolated Buffer-Perfused Mouse Heart and Is Associated With Improved Metabolic Homeostasis
44. Enhanced Publication Content for the manuscript: Risk of major adverse cardiovascular events with tofacitinib vs tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
45. Plain language summary for the manuscript: Risk of major adverse cardiovascular events with tofacitinib vs tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
46. Interleukin-6 Signaling, Soluble Glycoprotein 130, and Inflammation in Heart Failure
47. Instability in NAD+ metabolism leads to impaired cardiac mitochondrial function and communication
48. Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation
49. Tetradecylthioacetic Acid Increases Fat Metabolism and Improves Cardiac Function in Experimental Heart Failure
50. Author response: Instability in NAD+ metabolism leads to impaired cardiac mitochondrial function and communication
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.